{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T04:57:35Z","timestamp":1787029055179,"version":"build-2736575974"},"reference-count":128,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2021,4,29]],"date-time":"2021-04-29T00:00:00Z","timestamp":1619654400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Molecules"],"abstract":"<jats:p>Hemostasis disorders play an important role in the pathogenesis, clinical manifestations, and outcome of COVID-19. First of all, the hemostasis system suffers due to a complicated and severe course of COVID-19. A significant number of COVID-19 patients develop signs of hypercoagulability, thrombocytopenia, and hyperfibrinolysis. Patients with severe COVID-19 have a tendency toward thrombotic complications in the venous and arterial systems, which is the leading cause of death in this disease. Despite the success achieved in the treatment of SARS-CoV-2, the search for new effective anticoagulants, thrombolytics, and fibrinolytics, as well as their optimal dose strategies, continues to be relevant. The wide therapeutic potential of seaweed sulfated polysaccharides (PSs), including anticoagulant, thrombolytic, and fibrinolytic activities, opens up new possibilities for their study in experimental and clinical trials. These natural compounds can be important complementary drugs for the recovery from hemostasis disorders due to their natural origin, safety, and low cost compared to synthetic drugs. In this review, the authors analyze possible pathophysiological mechanisms involved in the hemostasis disorders observed in the pathological progression of COVID-19, and also focus the attention of researchers on seaweed PSs as potential drugs aimed to correction these disorders in COVID-19 patients. Modern literature data on the anticoagulant, antithrombotic, and fibrinolytic activities of seaweed PSs are presented, depending on their structural features (content and position of sulfate groups on the main chain of PSs, molecular weight, monosaccharide composition and type of glycosidic bonds, the degree of PS chain branching, etc.). The mechanisms of PS action on the hemostasis system and the issues of oral bioavailability of PSs, important for their clinical use as oral anticoagulant and antithrombotic agents, are considered. The combination of the anticoagulant, thrombolytic, and fibrinolytic properties, along with low toxicity and relative cheapness of production, open up prospects for the clinical use of PSs as alternative sources of new anticoagulant and antithrombotic compounds. However, further investigation and clinical trials are needed to confirm their efficacy.<\/jats:p>","DOI":"10.3390\/molecules26092618","type":"journal-article","created":{"date-parts":[[2021,4,30]],"date-time":"2021-04-30T05:10:55Z","timestamp":1619759455000},"page":"2618","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["The Potency of Seaweed Sulfated Polysaccharides for the Correction of Hemostasis Disorders in COVID-19"],"prefix":"10.3390","volume":"26","author":[{"given":"Tatyana A.","family":"Kuznetsova","sequence":"first","affiliation":[{"name":"G.P. Somov Institute of Epidemiology and Microbiology, Russian Federal Service for Surveillance on Consumer Rights Protection and Human Wellbeing, 690087 Vladivostok, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4456-808X","authenticated-orcid":false,"given":"Boris G.","family":"Andryukov","sequence":"additional","affiliation":[{"name":"G.P. Somov Institute of Epidemiology and Microbiology, Russian Federal Service for Surveillance on Consumer Rights Protection and Human Wellbeing, 690087 Vladivostok, Russia"},{"name":"School of Biomedicine, Far Eastern Federal University (FEFU), 690091 Vladivostok, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6450-840X","authenticated-orcid":false,"given":"Ilona D.","family":"Makarenkova","sequence":"additional","affiliation":[{"name":"G.P. Somov Institute of Epidemiology and Microbiology, Russian Federal Service for Surveillance on Consumer Rights Protection and Human Wellbeing, 690087 Vladivostok, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatyana S.","family":"Zaporozhets","sequence":"additional","affiliation":[{"name":"G.P. Somov Institute of Epidemiology and Microbiology, Russian Federal Service for Surveillance on Consumer Rights Protection and Human Wellbeing, 690087 Vladivostok, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalya N.","family":"Besednova","sequence":"additional","affiliation":[{"name":"G.P. Somov Institute of Epidemiology and Microbiology, Russian Federal Service for Surveillance on Consumer Rights Protection and Human Wellbeing, 690087 Vladivostok, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ludmila N.","family":"Fedyanina","sequence":"additional","affiliation":[{"name":"School of Biomedicine, Far Eastern Federal University (FEFU), 690091 Vladivostok, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergey P.","family":"Kryzhanovsky","sequence":"additional","affiliation":[{"name":"Medical Association of the Far Eastern Branch of the Russian Academy of Sciences, 690022 Vladivostok, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mikhail Yu.","family":"Shchelkanov","sequence":"additional","affiliation":[{"name":"G.P. Somov Institute of Epidemiology and Microbiology, Russian Federal Service for Surveillance on Consumer Rights Protection and Human Wellbeing, 690087 Vladivostok, Russia"},{"name":"School of Biomedicine, Far Eastern Federal University (FEFU), 690091 Vladivostok, Russia"},{"name":"Federal Scientific Center of the Eastern Asia Terrestrial Biodiversity, Far Eastern Branch of Russian Academy of Sciences, 690091 Vladivostok, Russia"},{"name":"National Scientific Center of Marine Biology, Far Eastern Branch of Russian Academy of Sciences, 690091 Vladivostok, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2021,4,29]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1007\/s11239-020-02129-0","article-title":"Pulmonary intravascular coagulation in COVID-19: Possible pathogenesis and recommendations on anticoagulant\/thrombolytic therapy","volume":"50","year":"2020","journal-title":"J. Thromb. Thrombolysis"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1097\/CCM.0000000000004458","article-title":"Coagulopathy of coronavirus disease","volume":"48","author":"Iba","year":"2020","journal-title":"Crit. Care Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1111\/jth.14768","article-title":"Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia","volume":"18","author":"Tang","year":"2020","journal-title":"J. Thromb. Haemost."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1055\/s-0041-1722992","article-title":"COVID-19 and Its Implications for Thrombosis and Anticoagulation","volume":"42","author":"Berkman","year":"2021","journal-title":"Semin Respir Crit. Care Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.thromres.2020.04.013","article-title":"Incidence of thrombotic complications in critically ill ICU patients with COVID-19","volume":"191","author":"Klok","year":"2020","journal-title":"Thromb. Res."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Tan, B.K., Mainbourg, S., Friggeri, A., Bertoletti, L., Douplat, M., Dargaud, Y., Grange, C., Lobbes, H., Provencher, S., and Lega, J.C. (2021). Arterial and venous thromboembolism in COVID-19: A study-level meta-analysis. Thorax, 23.","DOI":"10.1136\/thoraxjnl-2020-215383"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1111\/jth.14817","article-title":"Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy","volume":"18","author":"Tang","year":"2020","journal-title":"J. Thromb. Haemost."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1111\/jth.14810","article-title":"ISTH interim guidance on recognition and management of coagulopathy in COVID-19","volume":"18","author":"Thachil","year":"2020","journal-title":"J. Thromb. Haemost."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1111\/bjh.16727","article-title":"Thromboembolic risk and anticoagulant therapy in COVID-19 patients: Emerging evidence and call for action","volume":"189","author":"Kollias","year":"2020","journal-title":"Br. J. Haematol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1186\/s13054-020-03375-7","article-title":"Dosing of thromboprophylaxis and mortality in critically ill COVID-19 patients","volume":"24","author":"Jonmarker","year":"2020","journal-title":"Crit. Care"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1186\/s13063-020-04689-1","article-title":"Anticoagulation in critically ill patients on mechanical ventilation suffering from COVID-19 disease, The ANTI-CO trial: A structured summary of a study protocol for a randomized controlled trial","volume":"21","author":"Kharma","year":"2020","journal-title":"Trials"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.thromres.2020.09.026","article-title":"Therapeutic versus prophylactic anticoagulation for severe COVID-19: A randomized phase II clinical trial (HESACOVID)","volume":"196","author":"Lemos","year":"2020","journal-title":"Thromb. Res."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.jacc.2020.05.001","article-title":"Association of treatment dose anticoagulation within-hospital survival among hospitalized patients with COVID-19","volume":"76","author":"Paranjpe","year":"2020","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1007\/s10811-016-0974-5","article-title":"Algae as nutritional and functional food sources: Revisiting our understanding","volume":"29","author":"Wells","year":"2017","journal-title":"J. Appl. Phycol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"404","DOI":"10.3181\/00379727-94-22960","article-title":"Isolation of anticoagulant fractions from crude fucoidan","volume":"94","author":"Springer","year":"1957","journal-title":"Proc. Soc. Exp. Biol. Med."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1016\/j.procbio.2012.06.016","article-title":"Novel procedures for the extraction of fucoidan from brown algae","volume":"47","author":"Hahn","year":"2012","journal-title":"Process Biochem."},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Menshova, R.V., Shevchenko, N.M., Imbs, T.I., Zvyagintseva, T.N., Maluarenko, O.S., Zaporoshets, T.S., Besednova, N.N., and Ermakova, S.P. (2016). Fucoidans from brown alga Fucus evanescens: Structure and biological activity. Front. Mar. Sci., 3.","DOI":"10.3389\/fmars.2016.00129"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.ijbiomac.2013.08.036","article-title":"Sulfated polysaccharides as bioactive agents from marine algae","volume":"62","author":"Ngo","year":"2013","journal-title":"Int. J. Boil. Macromol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"115497","DOI":"10.1016\/j.carbpol.2019.115497","article-title":"Structural characterization of ulvan extracted from Ulva clathRata assisted by an ulvan lyase","volume":"229","author":"Chi","year":"2020","journal-title":"Carbohydr. Polym."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"2291","DOI":"10.1080\/14786419.2017.1408098","article-title":"Structure, conformation in aqueous solution and antimicrobial activity of ulvan extracted from green seaweed Ulva reticulate","volume":"32","author":"Tran","year":"2018","journal-title":"Nat. Prod. Res."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.carbpol.2019.04.074","article-title":"Ulvan, a bioactive marine sulphated polysaccharide as a key constituent of hybrid biomaterials: A review","volume":"218","author":"Tziveleka","year":"2019","journal-title":"Carbohydr. Polym."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"115280","DOI":"10.1016\/j.carbpol.2019.115280","article-title":"A sulfated glucuronorhamnan from the green seaweed Monostroma nitidum: Characteristics of its structure and antiviral activity","volume":"227","author":"Wang","year":"2020","journal-title":"Carbohydr. Polym."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.carbpol.2017.02.011","article-title":"Compositional and structural characteristics of sulfated polysaccharide from Enteromorpha prolifera","volume":"165","author":"Yu","year":"2017","journal-title":"Carbohydr. Polym."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.lwt.2016.12.038","article-title":"Effects of different carrageenan types on the rheological and water-holding properties of tofu","volume":"78","author":"Shen","year":"2017","journal-title":"LWT"},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Torres, M., Fl\u00f3rez-Fern\u00e1ndez, N., and Dom\u00ednguez, H. (2019). Integral Utilization of Red Seaweed for Bioactive Production. Mar. Drugs, 17.","DOI":"10.3390\/md17060314"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.carbpol.2018.06.086","article-title":"Carrageenan based hydrogels for drug delivery, tissue engineering and wound healing","volume":"198","author":"Yegappan","year":"2018","journal-title":"Carbohydr. Polym."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.carbpol.2006.03.002","article-title":"An anticoagulative polysaccharide from an enzymatic hydrolysate of Ecklonia cava","volume":"66","author":"Athukorala","year":"2006","journal-title":"Carbohydr. Polym."},{"key":"ref_28","first-page":"291","article-title":"Sulfated polysaccharides and their anticoagulant activity: A review","volume":"46","author":"Mestechkina","year":"2010","journal-title":"Prikl. Biokhim. Mikrobiol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1590\/S0100-879X2005000400005","article-title":"Partial characterization and anticoagulant activity of a heterofucan from the brown seaweed Padina gymnospora","volume":"38","author":"Silva","year":"2005","journal-title":"Braz. J. Med. Biol. Res."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.ijbiomac.2009.10.015","article-title":"Potential antioxidant and anticoagulant capacity of low molecular weight fucoidan fractions extracted from Laminaria japonica","volume":"46","author":"Wang","year":"2010","journal-title":"Int. J. Biol. Macromol."},{"key":"ref_31","first-page":"373","article-title":"Effect of sulfation on the structure and anticoagulant activity of ulvan extracted from green seaweed Ulva reticulata","volume":"54","author":"Luong","year":"2016","journal-title":"Vietnam J. Sci. Technol."},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Liu, X., Du, P., Liu, X., Cao, S., Qin, L., He, M., He, X., and Mao, W. (2018). Anticoagulant properties of a green algal rhamnan-type sulfated polysaccharide and its low-molecular-weight fragments prepared by mild acid degradation. Mar. Drugs, 16.","DOI":"10.3390\/md16110445"},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Adrien, A., Bonnet, A., Dufour, D., Baudouin, S., Maugard, T., and Bridiau, N. (2019). Anticoagulant activity of sulfated ulvan isolated from the green macroalga Ulva rigida. Mar. Drugs, 17.","DOI":"10.3390\/md17050291"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1016\/j.carbpol.2011.02.042","article-title":"Structural characterization of an anticoagulant-active sulfated polysaccharide isolated from green alga Monostroma latissimum","volume":"85","author":"Li","year":"2011","journal-title":"Carbohydr. Polym."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1007\/s10126-015-9643-y","article-title":"Structural features and anti-coagulant activity of the sulphated polysaccharide SPS-CF from a green alga Capsosiphon fulvescens","volume":"17","author":"Synytsya","year":"2015","journal-title":"Mar. Biotechnol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"2326","DOI":"10.1016\/j.carres.2007.06.019","article-title":"A sulfated fucan from the brown alga Laminaria cichorioides has mainly heparin cofactor II-dependent anticoagulant activity","volume":"342","author":"Yoon","year":"2007","journal-title":"Carbohyd. Res."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.ijbiomac.2008.08.006","article-title":"Effects of molecular weight and hydrolysis conditions on anticancer activity of fucoidans from sporophyll of Undaria pinnatifida","volume":"43","author":"Yang","year":"2008","journal-title":"Int. J. Biol. Macromol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1093\/glycob\/cwi021","article-title":"Selective cleavage and anticoagulant activity of a sulfated fucan: Stereospecific removal of a 2-sulfate ester from the polysaccharide by mild acid hydrolysis, preparation of oligosaccharides, and heparin cofactor II-dependent anticoagulant activity","volume":"15","author":"Pomin","year":"2005","journal-title":"Glycobiology"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1002\/ddr.2","article-title":"Relationship between antithrombotic activities of fucans and their structure","volume":"51","author":"Chaubet","year":"2000","journal-title":"Drug. Dev. Res."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.carbpol.2018.02.035","article-title":"Size-dependent pharmacological activities of differently degraded fucoidan fractions from Fucus vesiculosus","volume":"189","author":"Lahrsen","year":"2018","journal-title":"Carbohyd. Polym."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.thromres.2017.11.015","article-title":"Thrombolytic fucoidans inhibit the tPA-PAI1 complex, indicating activation of plasma tissue-type plasminogen activator is a mechanism of fucoidan-mediated thrombolysis in a mouse thrombosis model","volume":"161","author":"Choi","year":"2018","journal-title":"Thromb. Res."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1097\/MBC.0000000000000522","article-title":"Stimulatory effect of an algal fucoidan on the release of vascular endothelial tissue-type plasminogen activator as a mechanism of fucoidan-mediated thrombolysis","volume":"27","author":"Min","year":"2016","journal-title":"Blood Coagul. Fibrinolysis"},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Cao, S., He, X., Qin, L., He, M., Yang, Y., Liu, Z., and Mao, W. (2019). Anticoagulant and antithrombotic properties in vitro and in vivo of a novel sulfated polysaccharide from marine green alga Monostroma nitidum. Mar. Drugs, 17.","DOI":"10.3390\/md17040247"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.biomaterials.2017.11.047","article-title":"Thrombolytic therapy based on fucoidan-functionalized polymer nanoparticles targeting P-selectin","volume":"156","author":"Juenet","year":"2018","journal-title":"Biomaterials"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1097\/01.mbc.0000224847.12131.89","article-title":"Effect of native fucoidan, sulfated fucoidan, heparin and 6-aminohexanoic acid on the activation of glutamic-plasminogen by urokinase: Role of NaCl","volume":"17","author":"Hall","year":"2006","journal-title":"Blood Coagul. Fibrinolysis"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.carbpol.2005.08.064","article-title":"Effect of oversulfation on the chemical and biological properties of fucoidan","volume":"63","author":"Qiu","year":"2006","journal-title":"Carbohydr. Polym."},{"key":"ref_47","first-page":"51","article-title":"Heparin-induced thrombosis with a normal platelet count","volume":"9","author":"Alvarez","year":"2007","journal-title":"Crit. Care Resusc."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"153","DOI":"10.2174\/187152907781745251","article-title":"Heparin induced thrombocytopenia: Pathogenetic, clinical, diagnostic and therapeutic aspects","volume":"7","author":"Castelli","year":"2007","journal-title":"Cardiovasc. Hematol. Disord. Drug Targets"},{"key":"ref_49","doi-asserted-by":"crossref","unstructured":"Suleria, H.A.R., Masci, P.P., Zhao, K.N., Addepalli, R., Chen, W., Osborne, S.A., and Gobe, G.C. (2017). Anti-coagulant and anti-thrombotic properties of blacklip abalone (Haliotis rubra): In Vitro and animal studies. Mar. Drugs, 15.","DOI":"10.3390\/md15080240"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"281","DOI":"10.2174\/157016309789869001","article-title":"Therapeutic use of heparin beyond anticoagulation","volume":"6","author":"Ludwig","year":"2009","journal-title":"Curr. Drug Discov. Technol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"20824","DOI":"10.1074\/jbc.M308688200","article-title":"Antithrombin-mediated anticoagulant activity of sulfated polysaccharides: Different mechanisms for heparin and sulfated galactans","volume":"279","author":"Melo","year":"2004","journal-title":"J. Biol. Chem."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1023\/B:BEBM.0000017096.72246.1f","article-title":"Anticoagulant activity of fucoidan from brown algae Fucus evanescens of the Okhotsk Sea","volume":"136","author":"Kuznetsova","year":"2003","journal-title":"Bull. Exp. Biol. Med."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1007\/s10517-008-0267-3","article-title":"Inhibition of thrombin and factor Xa by Fucus evanescens fucoidan and its modified analogs","volume":"146","author":"Lapikova","year":"2008","journal-title":"Bull. Exp. Biol. Med."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1007\/s10811-006-9149-0","article-title":"Sulfated polysaccharide purified from Ecklonia cava accelerates antithrombin III-mediated plasma proteinase inhibition","volume":"19","author":"Jung","year":"2007","journal-title":"J. Appl. Phycol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.jmgm.2007.01.008","article-title":"Conformation of sulfated galactan and sulfated fucan in aqueous solutions: Implications to their anticoagulant activities","volume":"26","author":"Becker","year":"2007","journal-title":"J. Mol. Graph. Model."},{"key":"ref_56","doi-asserted-by":"crossref","unstructured":"Wang, Y., Xing, M., Cao, Q., Ji, A., Liang, H., and Song, S. (2019). Biological Activities of Fucoidan and the Factors Mediating Its Therapeutic Effects: A Review of Recent Studies. Mar. Drugs, 17.","DOI":"10.3390\/md17030183"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/j.fct.2004.12.001","article-title":"Toxicological evaluation of fucoidan extracted from Laminaria japonica in Wistar rats","volume":"43","author":"Li","year":"2005","journal-title":"Food Chem. Toxicol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1182\/blood-2007-07-098913","article-title":"Efficacy and safety of a new-class hemostatic drug candidate, AV513, in dogs with hemophilia A","volume":"111","author":"Prasad","year":"2008","journal-title":"Blood"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1089\/jmf.2007.0127","article-title":"Toxicological evaluation of fucoidan from Cladosiphon okamuranus","volume":"11","author":"Gideon","year":"2008","journal-title":"J. Med. Food."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.thromres.2016.03.008","article-title":"Antithrombotic activity of oral administered low molecular weight fucoidan from Laminaria japonica","volume":"144","author":"Zhao","year":"2016","journal-title":"Thromb. Res."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1016\/S0140-6736(20)30937-5","article-title":"Endothelial cell infection and endotheliitis in COVID-19","volume":"395","author":"Varga","year":"2020","journal-title":"Lancet"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1001\/jamacardio.2020.1282","article-title":"Coronavirus Disease 2019 (COVID-19) infection and renin angiotensin system blockers","volume":"5","author":"Bavishi","year":"2020","journal-title":"JAMA Cardiol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"2033","DOI":"10.1182\/blood.2020006000","article-title":"COVID\u201119 and its implications for thrombosis and anticoagulation","volume":"135","author":"Connors","year":"2020","journal-title":"Blood"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"E438","DOI":"10.1016\/S2352-3026(20)30145-9","article-title":"Coagulation abnormalities and thrombosis in patients with COVID\u201119","volume":"7","author":"Levi","year":"2020","journal-title":"Lancet Haematol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1111\/jth.14818","article-title":"Pulmonary thrombosis in 2019-nCoV pneumonia?","volume":"18","author":"Marongiu","year":"2020","journal-title":"J. Tromb. Haemost."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1186\/s12931-020-01462-5","article-title":"The pathophysiology of \u2018happy\u2019 hypoxemia in COVID-19","volume":"21","author":"Dhont","year":"2020","journal-title":"Respir. Res."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1038\/s41401-020-00554-8","article-title":"Hypoxia, HIF-1\u03b1, and COVID-19: From pathogenic factors to potential therapeutic targets","volume":"41","author":"Serebrovska","year":"2020","journal-title":"Acta Pharmacol. Sin."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1007\/s12291-020-00935-0","article-title":"Pneumolysis and \u00abSilent Hypoxemia\u00bb in COVID-19","volume":"36","year":"2021","journal-title":"Indian J. Clin. Biochem."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1093\/cid\/ciaa248","article-title":"Dysregulation of immune response in patients with COVID-19 in Wuhan, China","volume":"71","author":"Qin","year":"2020","journal-title":"Clin. Infect. Dis."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1038\/s41577-020-0305-6","article-title":"In the eye of the COVID-19 cytokine storm","volume":"20","author":"Vaninov","year":"2020","journal-title":"Nat. Rev. Immunol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"102452","DOI":"10.1016\/j.jaut.2020.102452","article-title":"Can we use interleukin-6 (IL-6) blockade for coronavirus disease 2019 (COVID-19)-induced cytokine release syndrome (CRS)?","volume":"111","author":"Liu","year":"2020","journal-title":"J. Autoimmun."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1515\/cclm-2020-0188","article-title":"Prominent changes in blood coagulation of patients with SARS-CoV-2 infection","volume":"58","author":"Han","year":"2020","journal-title":"Clin. Chem. Lab. Med."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"2163","DOI":"10.1038\/s41375-020-0910-1","article-title":"Hematological features of persons with COVID-19","volume":"34","author":"Li","year":"2020","journal-title":"Leukemia"},{"key":"ref_74","doi-asserted-by":"crossref","unstructured":"Yang, X., Yang, Q., Wang, Y., Wu, Y., Xu, J., Yu, Y., and Shang, Y. (2020). Thrombocytopenia and its association with mortality in patients with COVID-19. J. Thromb. Haemost., 18.","DOI":"10.1111\/jth.14848"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1080\/09537104.2020.1754383","article-title":"Association between platelet parameters and mortality in coronavirus disease 2019: Retrospective cohort study","volume":"31","author":"Liu","year":"2020","journal-title":"Platelets"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1111\/jth.14888","article-title":"Incidence of venous thromboembolism in hospitalized patients with COVID\u201119","volume":"18","author":"Middeldorp","year":"2020","journal-title":"J. Thromb. Haemost."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"1076029620918308","DOI":"10.1177\/1076029620918308","article-title":"Hemorrhagic Problem Among the Patients With COVID-19: Clinical Summary of 41 Thai Infected Patients","volume":"26","author":"Joob","year":"2020","journal-title":"Clin. Appl. Thromb. Hemost."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1161\/CIRCRESAHA.120.317447","article-title":"The Emerging Threat of (Micro) Thrombosis in COVID-19 and Its Therapeutic Implications","volume":"127","author":"McFadyen","year":"2020","journal-title":"Circ. Res."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1007\/s00277-020-04019-0","article-title":"Mechanism of thrombocytopenia in COVID-19 patients","volume":"99","author":"Xu","year":"2020","journal-title":"Ann. Hematol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.thromres.2020.06.008","article-title":"Mechanisms involved in the development of thrombocytopenia in patients with COVID-19","volume":"193","author":"Zhang","year":"2020","journal-title":"Thromb. Res."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.cca.2020.03.022","article-title":"Thrombocytopenia is associated with severe coronavirus disease 2019 (COVID\u201119) infections: A meta\u2011analysis","volume":"506","author":"Lippi","year":"2020","journal-title":"Clin. Chim. Acta"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.1111\/jth.14832","article-title":"Exploring possible mechanisms for COVID-19 induced thrombocytopenia: Unanswered Questions","volume":"18","author":"Amgalan","year":"2020","journal-title":"J. Thromb. Haemost."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"10061","DOI":"10.1016\/j.blre.2019.100613","article-title":"From unfractionated heparin to pentasaccharide: Paradigm of rigorous science growing in the understanding of the in vivo thrombin generation","volume":"39","author":"Spadarella","year":"2020","journal-title":"Blood Rev."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"188S","DOI":"10.1378\/chest.126.3_suppl.188S","article-title":"Heparin and low-molecular-weight heparin: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy","volume":"126","author":"Hirsh","year":"2004","journal-title":"Chest"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"2308","DOI":"10.1182\/blood.V97.8.2308","article-title":"Prothrombin protects factor Xa in the prothrombinase complex from inhibition by the heparin-antithrombin complex","volume":"97","author":"Rezaie","year":"2001","journal-title":"Blood"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1055\/s-2007-982080","article-title":"Variability of Heparins and Heterogeneity of Low Molecular Weight Heparins","volume":"33","author":"Bianchini","year":"2007","journal-title":"Semin Thromb Hemost."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"1902","DOI":"10.1111\/j.1538-7836.2011.04445.x","article-title":"Low-molecular-weight heparins vs. unfractionated heparin in the setting of percutaneous coronary intervention for ST-elevation myocardial infarction: A meta-analysis","volume":"9","author":"Navarese","year":"2011","journal-title":"J. Thromb. Haemost."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1111\/j.1365-2141.1992.tb06437.x","article-title":"Inhibition of thrombin generation by heparin and low molecular weight (LMW) heparins in the absence and presence of platelet factor 4 (PF4)","volume":"82","author":"Padilla","year":"1992","journal-title":"Br. J. Haematol."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"171","DOI":"10.3109\/15412555.2013.831062","article-title":"Efficacy of low molecular weight heparin in patients with acute exacerbation of chronic obstructive pulmonary disease receiving ventilatory support","volume":"11","author":"Qian","year":"2014","journal-title":"COPD"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1136\/bmj.38733.466748.7C","article-title":"Efficacy and safety of fondaparinux for the prevention of venous thromboembolism in older acute medical patients: Randomised placebo controlled trial","volume":"332","author":"Cohen","year":"2006","journal-title":"BMJ"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.thromres.2020.05.039","article-title":"Thrombosis risk associated with COVID-19 infection. A scoping review","volume":"192","author":"Chehade","year":"2020","journal-title":"Thromb. Res."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1111\/jth.14871","article-title":"Direct oral anticoagulant plasma levels\u2019 striking increase in severe COVID-19 respiratory syndrome patients treated with antiviral agents: The Cremona experience","volume":"18","author":"Testa","year":"2020","journal-title":"J. Thromb. Haemost."},{"key":"ref_93","unstructured":"University of Liverpool (2020, April 23). COVID-19 Drug Interactions. Available online: https:\/\/www.covid19-druginteractions.org\/prescribing-resources."},{"key":"ref_94","first-page":"167","article-title":"COVID-19 and haemostasis: A position paper from Italian society on thrombosis and haemostasis (SISET)","volume":"18","author":"Marietta","year":"2020","journal-title":"Blood Transfus."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1016\/j.thromres.2006.10.026","article-title":"The anti-inflammatory effects of heparin and related compounds","volume":"122","author":"Young","year":"2008","journal-title":"Thromb. Res."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1111\/jth.14821","article-title":"The versatile heparin in COVID-19","volume":"18","author":"Thachil","year":"2020","journal-title":"J. Thromb. Haemost."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1160\/TH11-09-0611","article-title":"Infections and inflammatory diseases as risk factors for venous thrombosis. A systematic review","volume":"107","author":"Tichelaar","year":"2012","journal-title":"Thromb. Haemost."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1160\/TH16-08-0620","article-title":"More than an anticoagulant: Do heparins have direct anti-inflammatory effects?","volume":"117","author":"Poterucha","year":"2017","journal-title":"Thromb. Haemost."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1093\/ehjcvp\/pvaa036","article-title":"Anticoagulation in COVID-19","volume":"6","author":"Atallah","year":"2020","journal-title":"Eur. Heart J. Cardiovasc. Pharmacother."},{"key":"ref_100","first-page":"20","article-title":"Thromboinflammation in COVID-19 acute lung injury","volume":"35","author":"Mitchell","year":"2020","journal-title":"Paediatr. Respir. Rev."},{"key":"ref_101","doi-asserted-by":"crossref","unstructured":"Mycroft-West, C., Su, D., Elli, S., Guimond, S., Miller, G., Turnbull, J., Yates, E., Guerrini, M., Fernig, D., and Lima, M. (2020). The 2019 coronavirus (SARS-CoV-2) surface protein (Spike) S1 receptor binding domain undergoes conformational change upon heparin binding. BioRxiv.","DOI":"10.1101\/2020.02.29.971093"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.thromres.2020.04.028","article-title":"Thrombotic complications of patients admitted to intensive care with COVID-19 at a teaching hospital in the United Kingdom","volume":"191","author":"Thomas","year":"2020","journal-title":"Thromb. Res."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1007\/s00134-020-06062-x","article-title":"High risk of thrombosis in patients with severe SARS-CoV-2 infection: A multicenter prospective cohort study","volume":"46","author":"Helms","year":"2020","journal-title":"Intensive Care Med."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1007\/s11239-020-02145-0","article-title":"Heparin resistance in COVID-19 patients in the intensive care unit","volume":"50","author":"White","year":"2020","journal-title":"J. Thromb. Thrombolysis"},{"key":"ref_105","first-page":"11","article-title":"New coronavirus infection, hemostasis and heparin dosing problems: It is important to say now","volume":"2","author":"Bulanov","year":"2020","journal-title":"Tromboz Gemostaz i Reologiya"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1182\/bloodadvances.2020003763","article-title":"American Society of Hematology 2021 guidelines on the use of anticoagulation for thromboprophylaxis in patients with COVID-19","volume":"5","author":"Cuker","year":"2021","journal-title":"Blood Adv."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/S2213-2600(20)30243-5","article-title":"Pulmonary and cardiac pathology in Covid-19: The first autopsy series from New Orleans","volume":"8","author":"Fox","year":"2020","journal-title":"Lancet Respir. Med."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.recesp.2020.08.007","article-title":"The use of antiplatelet agents for arterial thromboprophylaxis in COVID-19","volume":"74","author":"Kow","year":"2021","journal-title":"Rev. Esp. Cardiol."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1111\/jth.14854","article-title":"The procoagulant pattern of patients with COVID-19 acute respiratory distress syndrome","volume":"18","author":"Ranucci","year":"2020","journal-title":"J. Thromb. Haemost."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1016\/j.apsb.2020.04.008","article-title":"Potential therapeutic effects of dipyridamole in the severely ill patients with COVID-19","volume":"10","author":"Liu","year":"2020","journal-title":"Acta Pharm. Sin. B"},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1097\/SHK.0000000000000745","article-title":"Prevention or treatment of ARDS with aspirin: A review of preclinical models and meta-analysis of clinical studies","volume":"47","author":"Panka","year":"2017","journal-title":"Shock"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1378\/chest.14-2701","article-title":"Linking genetics to ARDS pathogenesis: The role of the platelet","volume":"147","author":"Reilly","year":"2015","journal-title":"Chest"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1055\/s-0040-1713152","article-title":"Global COVID-19 Thrombosis Collaborative Group. Pharmacological Agents Targeting Thromboinflammation in COVID-19: Review and Implications for Future Research","volume":"120","author":"Bikdeli","year":"2020","journal-title":"Thromb. Haemost."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1002\/jmv.25770","article-title":"Diagnostic utility of clinical laboratory data determinations for patients with the severe COVID-19","volume":"92","author":"Gao","year":"2020","journal-title":"J. Med. Virol."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1159\/000512007","article-title":"Review Article. The Impact of COVID-19 Disease on platelets and coagulation","volume":"88","author":"Wool","year":"2021","journal-title":"Pathobiology"},{"key":"ref_116","doi-asserted-by":"crossref","unstructured":"Ahmadi, A., Moghadamtousi, S.Z., Abubakar, S., and Zandi, K. (2015). Antiviral Potential of Algae Polysaccharides Isolated from Marine Sources: A Review. BioMed. Res. Int., 10.","DOI":"10.1155\/2015\/825203"},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"2399","DOI":"10.2174\/0929867043364504","article-title":"Sulfated seaweed polysaccharides as antiviral agents","volume":"11","author":"Damonte","year":"2004","journal-title":"Curr. Med. Chem."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"2795","DOI":"10.3390\/md10122795","article-title":"The antiviral activities and mechanisms of marine polysaccharides: An overview","volume":"10","author":"Wang","year":"2012","journal-title":"Mar. Drugs"},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"470","DOI":"10.3934\/microbiol.2020028","article-title":"Biologically active compounds from marine organisms in the strategies for combating coronaviruses. Review","volume":"6","author":"Zaporozhets","year":"2020","journal-title":"AIMS Microbiol."},{"key":"ref_120","doi-asserted-by":"crossref","unstructured":"Apostolova, E., Lukova, P., Baldzhieva, A., Katsarov, P., Nikolova, M., Iliev, I., Peychev, L., Trica, B., Oancea, F., and Delattre, C. (2020). Immuno-modulatory and anti-inflammatory effects of fucoidan: A Review. Polymers, 12.","DOI":"10.3390\/polym12102338"},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1007\/s00253-015-7244-3","article-title":"Marine natural products with inflammatory activity","volume":"100","author":"Cheung","year":"2016","journal-title":"Appl. Microbiol. Biotechnol."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.ijbiomac.2019.02.043","article-title":"Characterization and anti-inflammatory effects of sulfated polysaccharide from the red seaweed Gelidium pacificum Okamura","volume":"129","author":"Cui","year":"2019","journal-title":"Int. J. Biol. Macromol."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"68","DOI":"10.5897\/AJPP2016.4695","article-title":"Pharmacological, pharmaceutical, cosmetic and diagnostic applications of sulfated polysaccharides from marine algae and bacteria","volume":"11","author":"Majee","year":"2017","journal-title":"Afr. J. Pharm. Pharmacol."},{"key":"ref_124","doi-asserted-by":"crossref","unstructured":"Giriwono, P.E., Iskandriati, D., Tan, C.P., and Andarwulan, N. (2019). Sargassum seaweed as a source of anti-inflammatory substances and the potential insight of the tropical species: A review. Mar. Drugs, 17.","DOI":"10.3390\/md17100590"},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"104873","DOI":"10.1016\/j.antiviral.2020.104873","article-title":"Characterization of heparin and severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) spike glycoprotein binding interactions","volume":"181","author":"Kim","year":"2020","journal-title":"Antiviral Res."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1038\/s41421-020-00192-8","article-title":"Sulfated polysaccharides effectively inhibit SARS-CoV-2 in vitro","volume":"6","author":"Kwon","year":"2020","journal-title":"Cell Discov."},{"key":"ref_127","first-page":"100623","article-title":"Antiviral activity of sulfated polysaccharides from marine algae and its application in combating COVID-19: Mini review","volume":"13","author":"Hans","year":"2021","journal-title":"Biores. Technol. Rep."},{"key":"ref_128","doi-asserted-by":"crossref","unstructured":"Pagarete, A., Ramos, A.S., Puntervoll, P., Allen, M.J., and Verdelho, V. (2021). Antiviral Potential of Algal Metabolites\u2014A Comprehensive Review. Mar. Drugs, 19.","DOI":"10.3390\/md19020094"}],"container-title":["Molecules"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1420-3049\/26\/9\/2618\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T05:55:42Z","timestamp":1760162142000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1420-3049\/26\/9\/2618"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,29]]},"references-count":128,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2021,5]]}},"alternative-id":["molecules26092618"],"URL":"https:\/\/doi.org\/10.3390\/molecules26092618","relation":{},"ISSN":["1420-3049"],"issn-type":[{"value":"1420-3049","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,29]]}}}